Hypoxia induces proteasome-dependent degradation of estrogen receptor α in ZR-75 breast cancer cells

Molecular Endocrinology

Volumn 16, Issue 10, 2002, Pages 2231-2242

  Stoner, Matthew ^a   Saville, Bradley ^b   Wormke, Mark ^a   Dean, Dana ^a   Burghardt, Robert ^a   Safe, Stephen ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEASOME; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR SP1;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL GROWTH; CONTROLLED STUDY; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RNA ANALYSIS; TRANSACTIVATION; TUMOR GROWTH;

BREAST NEOPLASMS; CELL DIVISION; CELL HYPOXIA; COBALT; CYSTEINE ENDOPEPTIDASES; ENDOTHELIAL GROWTH FACTORS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUPEPTINS; LYMPHOKINES; MULTIENZYME COMPLEXES; PROMOTER REGIONS (GENETICS); PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEINS; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; SP1 TRANSCRIPTION FACTOR; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036795452     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2001-0347     Document Type: Article

References (68)

1. Aplin JD 2000 Hypoxia and human placental development. J Clin Invest 105:559-560
2. Wenger RH, Gassmann M 1997 Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378:609-616
3. Bunn HF, Poyton RO 1996 Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 76:839-885
4. Richard DE, Berra E, Pouyssegur J 1999 Angiogenesis: how a tumor adapts to hypoxia. Biochem Biophys Res Commun 266:718-722
5. Semenza GL 2000 HIF-1 and human disease: one highly involved factor. Genes Dev 14:1983-1991
6. Semenza GL 2000 Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35:71-103
7. Höckel M, Vaupel P 2001 Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266-276
8. Semenza GL 1999 Perspectives on oxygen sensing. Cell 98:281-284
9. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15:551-578
10. Semenza GL 2000 HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 88:1474-1480
11. Zetter BR 1998 Angiogenesis and tumor metastasis. Annu Rev Med 49:407-424
12. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K 2000 Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203-211
13. Hanahan D, Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
14. Ferrara N, Davis-Smyth T 1997 The biology of vascular endothelial growth factor. Endocr Rev 18:4-25
15. Folkman J, Klagsburn M 1987 Angiogenic factors. Science 235:442-447
16. Claffey KP, Robinson GS 1996 Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 15: 165-176
17. Wakui S, Furusato M, Itoh T, Sasaki H, Akiyama A, Kinoshita I, Asano K, Tokuda T, Aizawa S, Ushigome S 1992 Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168:257-262
18. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579
19. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR 1993 Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 143:1255-1262
20. Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK 1995 Expression of vascular endothelial growth factor and its receptors fIt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506-516
21. Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S 1997 Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106
22. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA 1992 Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 340: 145-146
23. Gasparini G, Weidner N, Maluta S, Pozza F, Boracchi P, Mezzetti M, Testolin A, Bevilacqua P 1993 Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 55:739-744
24. Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E 2001 Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst 93:309-314
25. Saaristo A, Karpanen T, Alitalo K 2000 Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis. Oncogene 19:6122-6129
26. Brekken RA, Overholser JP, Stastny VA, Waltenberger J, Minna JD, Thorpe PE 2000 Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/ Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 60:5117-5124
27. Luo JC, Toyoda M, Shibuya M 1998 Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58:2594-2600
28. Asano M, Yukita A, Matsumoto T, Hanatani M, Suzuki H 1998 An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 17:185-190
29. Bae DG, Gho YS, Yoon WH, Chae CB 2000 Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis. J Biol Chem 275:13588-13596
30. Schlaeppi JM, Wood JM 1999 Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 18:473-481
31. Kondo S, Asano M, Suzuki H 1993 Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 194:1234-1241
32. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R 2000 p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 89:51-62
33. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J 2001 The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 61:2256-2260
34. 2 and β-estradiol induce VEGF in MCF-7 and MCF-7-5C cells: relationship to in vivo hypoxia. Breast Cancer Res Treat 67:51-60
35. Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Härkönen PL 1999 Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol 149:29-40
36. Mueller MD, Vigne JL, Minchenko A, Lebovic DI, Leitman DC, Taylor RN 2000 Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors α and β. Proc Natl Acad Sci USA 97: 10972-10977
37. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL 2000 Expression of hypoxia-inducible factor 1α in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88:2606-2618
38. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER 1989 A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484
39. Stoner M, Safe S 2001 Vascular endothelial growth factor (VEGF) is induced by 17β-estradiol in ZR-75 human breast cancer cell line. Toxicologist 153 (Abstract)
40. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, Poellinger L 1998 Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α. EMBO J 17:6573-6586
41. Griffiths L, Dachs GU, Bicknell R, Harris AL, Stratford IJ 1997 The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo. Cancer Res 57:570-572
42. Escoubet B, Planes C, Clerici C 1999 Hypoxia increases glyceraldehyde-3-phosphate dehydrogenase transcription in rat alveolar epithelial cells. Biochem Biophys Res Commun 266:156-161
43. Wormke M, Stoner M, Saville B, Safe S 2000 Crosstalk between estrogen receptor α and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteosomes. FEBS Lett 478:109-112
44. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW 1999 Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96: 1858-1862
45. El Khissiin A, Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Lett 448: 160-166
46. Alarid ET, Bakopoulos N, Solodin N 1999 Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol Endocrinol 13:1522-1534
47. Sathya G, Li W, Klinge CM, Anolik JH, Hilf R, Bambara RA 1997 Effects of multiple estrogen responsive elements, their spacing and location on estrogen response of reporter genes. Mol Endocrinol 11:1994-2003
48. Hirota K, Semenza GL 2001 Rac1 activity is required for the activation of hypoxia-inducible factor 1. J Biol Chem 276:21166-21172
49. Conrad PW, Freeman TL, Beitner-Johnson D, Millhorn DE 1999 EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J Biol Chem 274:33709-33713
50. Krtolica A, Krucher NA, Ludlow JW 1998 Hypoxia-induced pRB hypophosphorylation results from down-regulation of CDK and upregulation of PP1 activities. Oncogene 17:2295-2304
51. Wang GL, Jiang BH, Semenza GL 1995 Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem Biophys Res Commun 216:669-675
52. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL 2000 Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545
53. Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson AB, Stokoe D, Giaccia AJ 2000 Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14:391-396
54. Maity A, Solomon D 2000 Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia. Exp Cell Res 255:250-257
55. Discher DJ, Bishopric NH, Wu X, Peterson CA, Webster KA 1998 Hypoxia regulates β-enolase and pyruvate kinase-M promoters by modulating Sp1/Sp3 binding to a conserved GC element. J Biol Chem 273:26087-26093
56. Safe S, Qin C, McDougal A 1999 Development of selective aryl hydrocarbon receptor modulators (SARMs) for treatment of breast cancer. Expert Opin Investig Drugs 8:1385-1396
57. McDougal A, Wormke M, Calvin J, Safe S 2001 Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective Ah receptor modulator. Cancer Res 61: 3901-3907
58. Krishnan V, Porter W, Santostefano M, Wang X, Safe S 1995 Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol Cell Biol 15:6710-6719
59. Harper N, Wang X, Liu H, Safe S 1994 Inhibition of estrogen-induced progesterone receptor in MCF-7 human breast cancer cells by aryl hydrocarbon (Ah) receptor agonists. Mol Cell Endocrinol 104:47-55
60. Zacharewski TR, Bondy KL, McDonell P, Wu ZF 1994 Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17β-estradiol-induced pS2 expression. Cancer Res 54:2707-2713
61. Lu Y-F, Sun G, Wang X, Safe S 1996 Inhibition of prolactin receptor gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 human breast cancer cells. Arch Biochem Biophys 332:35-40
62. Gillesby B, Santostefano M, Porter W, Wu ZF, Safe S, Zacharewski T 1997 Identification of a motif within the 5′-regulatory region on pS2 which is responsible for Ap1 binding and TCDD-mediated suppression. Biochemistry 36:6080-6089
63. Nodland KI, Wormke M, Safe S 1997 Inhibition of estrogen-induced activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the MCF-7 human breast cancer and other cell lines transfected with vitellogenin A2 gene promoter constructs. Arch Biochem Biophys 338:67-72
64. Wang W, Smith R, Safe S 1998 Aryl hydrocarbon receptor-mediated antiestrogenicity in MCF-7 cells: modulation of hormone-induced cell cycle enzymes. Arch Biochem Biophys 356:239-248
65. Safe S 1995 Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol Therap 67: 247-281
66. 2-dependent modulation of mitochondrial fatty acid oxidation. J Biol Chem 276:27605-27612
67. Lonard DM, Nawaz Z, Smith CL, O'Malley BW 2000 The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 5:939-948
68. Goldberg MA, Dunning SP, Bunn HF 1988 Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science 242:1412-1415